Ethypharm Out-licenses Mesalazine NDDS to Solvay Pharma India Limited
Mumbai, January 20, 2009: Ethypharm India, a subsidiary of leading French Drug Delivery Company Ethypharm SA, announced today an out-licensing cum supply agreement for Mesalazine targeted release Pellets in Sachet form with Solvay Pharma India Limited.
The product has been developed by Ethypharm India and would be supplied from Ethypharm’s manufacturing facility on the outskirts of Mumbai as finished and packaged formulation for marketing and distribution by Solvay Pharma India Ltd.
Mesalazine is indicated for the treatment of Ulcerative Colitis. Ulcerative Colitis is a long-standing inflammatory disease of the lining of the large intestine (Colon). The symptoms include bloody diarrhea associated with pain and cramps in the abdomen. Meslazine Pellets in Sachets is particularly useful formulation for patients who have difficulty in swallowing with tablets. It provides an effective alternative to the conventional Mesalazine tablets. The Indian market of Mesalazine is approximately Rs 20 Crores annually and is expected to grow significantly with the addition of this Novel Drug Delivery System product.
“We are very pleased to partner with Solvay,†said Mr VK Singh, CEO of Ethypharm, “as they are best poised to take such a product to the market. The world market for this product is close to USD 2 bn. We see an immense opportunity to address an unmet medical need in this category and plan to bring more innovative products in this segment. This unique presentation in the sachet brings an element of convenience to the patientâ€, said Mr. Singh.
Ms Dominique Baum Managing Director of Solvay India commented: “Mesalazine will perfectly complement our product portfolio in the gastroenterology range†This speciality for the treatment of IBD will be available to the health care community under the brand name Rowasaâ€.
About Ethypharm:
Ethypharm is one of the world leaders in DDS technology offering variety of oral modified release formulations through its patented technologies. It focuses on developing, manufacturing and licensing pharmaceutical products based on its proprietary technologies. Ethypharm is a partner in life cycle management with many MNCs in India and abroad. The company has a special focus on pain management, cardiovascular, Gastroenterology, oncology and CNS products. Ethypharm also has unique distinction of a being a global leader in Narcotic products where it has a vast product portfolio.
About Solvay:
Solvay is an international chemical and pharmaceutical group with headquarters in Brussels. In India, Solvay is present in the Pharmaceutical sector through its group company Solvay Pharma India Ltd, listed at the BSE. Solvay Pharma India Ltd has presence in the field of Women’s Health, Gastroenterology, Mental Health and influenza vaccine. Solvay Pharma India Ltd. is head quartered at Mumbai and employs over 500 people throughout India.
For further details please contact:
Ethypharm ll Pvt. Ltd:
Amresh Kumar — 30619006
[email protected]
Escher Communications & PR
Archan Pradhan – 9820330505
Rashmi Nakaskar – 9819222195
[email protected] / [email protected]
